A randomized trial of icosapent ethyl in ambulatory patients with COVID-19.
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19.
复制标题
DOI：
10.1016/j.isci.2021.103040
复制
发表时间：
2021-09-24
期刊：
影响因子：
5.8
通讯作者：
Mazer CD
中科院分区：
文献类型：
--
作者：
Kosmopoulos A;Bhatt DL;Meglis G;Verma R;Pan Y;Quan A;Teoh H;Verma M;Jiao L;Wang R;Juliano RA;Kajil M;Kosiborod MN;Bari B;Berih AA;Aguilar M;Escano A;Leung A;Coelho I;Hibino M;Díaz R;Mason RP;Steg PG;Simon T;Go AS;Ambrosy AP;Choi R;Kushner AM;Leiter LA;Al-Omran M;Verma S;Mazer CD
2019 年冠状病毒病（COVID-19）大流行仍然是全世界发病率和死亡率相当高的一个来源。减轻症状、炎症反应或疾病进展的治疗选择是有限的。这项随机开放标签试验在加拿大多伦多招募了 100 名有症状的 COVID-19 门诊患者。结果表明，与接受常规治疗的患者相比，二十碳五烯乙酯（每天 8 g，持续 3 天，随后每天 4 g，持续 11 天）显着降低了高敏 C 反应蛋白 (hs-CRP)，并改善了症状。具体而言，在接受治疗的患者中，主要生物标志物终点（hs-CRP 的变化）显着降低了 25%（-0.5 mg/L，四分位距 [IQR] [-6.9,0.4]，组内 p = 0.011）。相反，在常规护理患者中观察到不显着的 5.6% 降低（-0.1 mg/L，IQR [-3.2,1.7]，组内 p = 0.51）。未经调整的组间主要生物标志物分析不显着（p = 0.082）。总体而言，本报告提供了少量样本中二十碳五烯乙酯对有症状的 COVID-19 门诊患者的早期抗炎作用的证据，包括初始耐受良好的负荷剂量。 ClinicalTrials.gov 标识符：NCT04412018。二十碳五烯乙酯队列中的 hs-CRP 显着降低（p 值 = 0.011） 与常规护理相比，治疗中的总症状患病率显着降低 与常规护理相比，治疗参与者的 FLU-PRO 评分显着降低 二十碳五烯乙酯负荷剂量（8 克/天，持续 3 天）耐受性良好的第一个证据 健康科学；药品
The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patients with symptomatic COVID-19 in Toronto, Canada. Results indicate that icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days) significantly reduced high-sensitivity C-reactive protein (hs-CRP) and improved symptomatology compared with patients assigned to usual care. Specifically, the primary biomarker endpoint, change in hs-CRP, was significantly reduced by 25% among treated patients (−0.5 mg/L, interquartile range [IQR] [−6.9,0.4], within-group p = 0.011). Conversely, a non-significant 5.6% reduction was observed among usual care patients (−0.1 mg/L, IQR [−3.2,1.7], within-group p = 0.51). An unadjusted between-group primary biomarker analysis was non-significant (p = 0.082). Overall, this report provides evidence of an early anti-inflammatory effect of icosapent ethyl in a modest sample, including an initial well-tolerated loading dose, in symptomatic outpatients with COVID-19. ClinicalTrials.gov Identifier: NCT04412018. hs-CRP was significantly reduced within the icosapent ethyl cohort (p value = 0.011) Total symptom prevalence was significantly reduced in treatment versus usual care Treated participants had significant FLU-PRO score reductions versus usual care First evidence of a well-tolerated icosapent ethyl loading dose (8 g/day for 3 days) Health sciences; Medicine
登录
查看更多内容
影响因子：
4.7
作者：
Regidor PA;Santos FG;Rizo JM;Egea FM
通讯作者：
Egea FM
在重度抑郁症和慢性炎症患者中补充eicosapentaenoic酸后，循环抗炎和促脂质介质循环抗炎和促脂质介质的剂量和时间依赖性增加。
DOI：
10.1016/j.plefa.2020.102219
发表时间：
2021-01
期刊：
Prostaglandins, leukotrienes, and essential fatty acids
影响因子：
--
作者：
Lamon-Fava S;So J;Mischoulon D;Ziegler TR;Dunlop BW;Kinkead B;Schettler PJ;Nierenberg AA;Felger JC;Maddipati KR;Fava M;Rapaport MH
通讯作者：
Rapaport MH
影响因子：
3.7
作者：
Han, Alison;Poon, Jiat-Ling;Memoli, Matthew J.
通讯作者：
Memoli, Matthew J.
脱糖苷升高患者对他汀类药物疗法的患者冠状动脉粥样硬化进展的影响：蒸发试验的最终结果。
影响因子：
39.3
作者：
Budoff MJ;Bhatt DL;Kinninger A;Lakshmanan S;Muhlestein JB;Le VT;May HT;Shaikh K;Shekar C;Roy SK;Tayek J;Nelson JR
通讯作者：
Nelson JR
DOI：
10.1016/j.xcrm.2020.100144
发表时间：
2020-11-17
期刊：
Cell reports. Medicine
影响因子：
--
作者：
Mueller AA;Tamura T;Crowley CP;DeGrado JR;Haider H;Jezmir JL;Keras G;Penn EH;Massaro AF;Kim EY
通讯作者：
Kim EY